MICHAEL W BONNEY
CIK 1219016 · Executive Chair · last filed 2026-07-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.89M
Companies
17
Total Filings
149
Lifetime Open-Market Net
-$39.82M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AUTL | Director | — | $2.07 | — | $0 | 1 | 2026-07-01 |
| IMUX | Director | — | $14.10 | — | $0 | 1 | 2026-06-29 |
| ALNY | Director | 20,804 | $216.98 | $4.51M | -$14.89M | 18 | 2025-08-19 |
| BMY | Director | 14,501 | $64.84 | $940.2K | $5.2K | 16 | 2021-07-01 |
| Kaleido Biosciences, Inc. (KLDO) Delisted | Executive Chair | 1,233,523 | $0.29 | $357.7K | $999.5K | 3 | 2021-07-01 |
| Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Director | 13,459 | $11.19 | $150.7K | $0 | 4 | 2021-06-03 |
| SRPT | Director | 9,126 | $17.18 | $156.8K | $173.5K | 5 | 2020-02-28 |
| CELGENE CORP /DE/ (CELGZ) Delisted | Director | 0 | — | — | $206.0K | 8 | 2019-11-22 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | Director | — | $0.00 | — | $0 | 2 | 2019-06-12 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | Director | — | $68.49 | — | $0 | 2 | 2016-06-17 |
| THW | Director | 10,917 | $13.81 | $150.8K | $200.3K | 1 | 2015-08-18 |
| NPS PHARMACEUTICALS INC (NPSP) Delisted | Director | 0 | — | — | -$46.5K | 40 | 2015-02-24 |
| CUBIST PHARMACEUTICALS INC (CBST.Z) Delisted | Chief Executive Officer | 0 | — | — | -$8.36M | 5 | 2015-01-21 |
| THQ | Director | 5,000 | $19.46 | $97.3K | $100.0K | 1 | 2014-07-29 |
| CUBIST PHARMACEUTICALS INC (CBST) Delisted | Chief Executive Officer | 168,700 | — | — | -$18.23M | 37 | 2013-07-02 |
| HQL | Director | 800 | $20.82 | $16.7K | $10.6K | 1 | 2012-03-12 |
| HQH | Director | 665 | $23.28 | $15.5K | $10.3K | 1 | 2012-03-12 |
Recent Filings · Page 2 of 15
149 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-08-04 | ALNY | Mixed | +16,029 | -$1.20M | EDGAR |
| 2023-05-19 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2021-08-03 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2021-07-19 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2021-07-01 | Kaleido Biosciences, Inc. (KLDO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-07-01 | BMY | Grant (A) | — | $0 | EDGAR |
| 2021-06-14 | BMY | Exer (M) | +902 | $0 | EDGAR |
| 2021-06-04 | BMY | Exer (M) | +2,949 | $0 | EDGAR |
| 2021-06-03 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-04-02 | BMY | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.